-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CHojA92tXcX4h/ZJyD/Ocoh55ROnD+NMlyHAdUwHMY1Iap9Z2Z2bYeIE9oOHkRvw
 U/vZ1Sx44wvKBHlV61kBww==

<SEC-DOCUMENT>0001130319-08-000489.txt : 20080611
<SEC-HEADER>0001130319-08-000489.hdr.sgml : 20080611
<ACCEPTANCE-DATETIME>20080611113632
ACCESSION NUMBER:		0001130319-08-000489
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080610
FILED AS OF DATE:		20080611
DATE AS OF CHANGE:		20080611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		08892513

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o41008e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of June 2008

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date:&nbsp;&nbsp;June&nbsp;10, 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="top">
        <TD width="70%"><IMG src="o41008o4100800.gif" alt="Oncolytics Biotech Logo"></TD>
        <TD width="30%">210, 1167 Kensington Crescent N.W.<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt"><B><HR align="left" size="1" width="100%" noshade></B>


<DIV align="left" style="font-size: 11pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2<BR>
Ovarian Cancer Clinical Trial with REOLYSIN</B><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 18pt"><B>CALGARY, AB, </B>&#151; <B>June&nbsp;10, 2008 </B>&#151; Oncolytics Biotech Inc. (&#147;Oncolytics&#148;) (TSX:ONC, NASDAQ:ONCY)
announced today that patient enrolment has started in a Phase 1/2 clinical trial for patients with
metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous (IV)&nbsp;and
intraperitoneal (IP)&nbsp;administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, Oncolytics&#146; proprietary formulation of
the human reovirus. The National Cancer Institute (NCI), part of the National Institutes of
Health, is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while
Oncolytics will provide clinical supplies of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. The Principal Investigator is
Dr.&nbsp;David E. Cohn, Associate Professor, Division of Gynecologic Oncology at The Ohio State
University College of Medicine in Columbus, Ohio.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">&#147;REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is an exciting agent to investigate in patients with ovarian cancer,&#148; said
Dr.&nbsp;Cohn. &#147;Targeting a specific alteration commonly present in these tumors will hopefully lead to
efficacy with minimal toxicity.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">&#147;We are looking forward to working closely with the NCI to examine the effects of using
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> with two concurrent methods of administration,&#148; said Dr.&nbsp;Brad Thompson,
President and CEO of Oncolytics. &#147;Our REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> clinical program has now expanded to
include ten Phase 1/2 or Phase 2 trials in the U.S. and the U.K. using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a
monotherapy or in combination with radiation or chemotherapy.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">In the Phase 1 portion of the trial, patients will receive a constant dose of IV
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> on days 1-5 every 28&nbsp;days, as well as an escalating dose of IP
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> on days 1-2 every 28&nbsp;days. In the Phase 2 portion of the study, patients will
receive a constant dose of IV REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> on days 1-5 every 28&nbsp;days as well as the Maximum
Tolerated Dose (MTD)&nbsp;of IP REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> from the Phase 1 portion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">The primary objectives of the Phase 1 trial are to determine the safety and tolerability of
intravenous and intraperitoneal administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, and the MTD of IP
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> when used with a fixed dose of IV REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. The primary objective
of the Phase 2 trial is to determine the objective response rate of treatment with IV and IP
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in patients with recurrent, platinum-refractory ovarian, peritoneal and tubal
carcinomas. The Phase 1/2 trial is expected to enroll up to 70 patients.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">The American Cancer Society estimates that more than 22,000 women will be diagnosed with ovarian
cancer in the U.S. in 2008, and more than 15,000 will die from it.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 18pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company&#146;s
expectations related to the U.S. NCI Phase I/II systemic and intraperitoneal administration
clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers, and the
Company&#146;s belief as to the potential of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer therapeutic, involve known
and unknown risks and uncertainties, which could cause the Company&#146;s actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects,
the efficacy of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer treatment, the tolerability of
REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> outside a controlled test, the success and timely completion of clinical
studies and trials, the Company&#146;s ability to successfully commercialize REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>,
uncertainties related to the research and development of pharmaceuticals and uncertainties related
to the regulatory process. Investors should consult the Company&#146;s quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to update these forward-looking
statements.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>
</DIV>

<DIV align="center" style="margin-top: 12pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc.<BR>
Cathy Ward<BR>
210, 1167 Kensington Cr NW<BR>
Calgary, Alberta T2N 1X7<BR>
Tel: 403.670.7377<BR>
Fax: 403.283.0858<BR>
<U>cathy.ward@oncolytics.ca</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group<BR>
Nick Hurst<BR>
325, 300 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. SW<BR>
Calgary, Alberta T2P 2V7<BR>
Tel: 403.538.4845<BR>
Fax: 403.237.6916<BR>
<U>nhurst@equicomgroup.com</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group<BR>
Erika Moran<BR>
11 Stone St, 3rd Floor<BR>
New York, NY 10004<BR>
Tel: 212.825.3210<BR>
Fax: 212.825.3229<BR>
<U>emoran@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o41008o4100800.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o41008o4100800.gif
M1TE&.#EA-`%!`+,*`/___\S,_\S,S)F9S)F9F9EFF69FF69F9C,S9C,`,___
M_P```````````````````"'Y!`$```H`+``````T`4$```3_4,E)J[U!",*)
M#E<HCF1IGFBJKFSKOG!\`D)Q)'BNXT<AR,"@<$@L&H_`@6'';.(,/Z1T2JU:
MKRX``>'L-A$$`'9,+IO/*"VW>S@8..VU$XRNV^_XH4"N0Q@&("("2GPY"%%Y
MB8J+B@!+3%`K`H\[!6*,F)F:4WL[8)<M`92&@9NFIZ@J`X4&H#`!-WV(J;2U
MM`.>LT"=AKJVO\!YN#JM1@%\A\'*RV<"E5.CR<S3U$B\.`-5T:[5W=XM`'S9
M5J,'W^?H**,%8Z,$Z?#Q%,XY!F3A.K[R^]1R"-Q6KIGC1Y`:@7QG#N;05[`A
M*GQ/ZOAS2+&60ARES-##P;"BQT1R_^S9B95@X,>3BC8FR-A,!TN4,,]0$GE'
MSKN8.,_(Z4CF(H*<0,>H3!1`!\"@2(M<I(EG9]*G1RC=S",5CX:K/$E@U0#5
MQ-:L%S1T\"#@I0*GB2Z:O'`Q@;2P.=:2`$!H3J02=;_\.;$TA3BM$RF,\K*#
M*06?*&H4,O3&K`2Z))T<\##!:$I#(]JZ9;A1;@@UA''\R[QXSE01:E-<2S`N
MK#^6D4/G.'U8AXE5LM]66.TV#A,$((KF6`3`-NK?^CJ7N.9'`"@:!'J,`!#Y
M3\8``R(#SQQ7Q>K6\_P!S/`UY%?G(=J2@*7CP(!9&PP8<*SR$+?X"*0I7V0\
M_1=?^XDPS/\31YU`DFX6,%>@`JFI`!$VNXF'`DFTD:">(/Z`%4)@)P282']L
MU9/A;MT)0LP+`R8`EDJ&U<8#"P^R-H&"*5"8PH4;&K)@"1)V6*(B(%J@UH.Z
M>6C!@3ORB)D)?!38X`HQ9D-CC;/=&*2+'*'8AP])*F`D'E=B:0YSB'PY@7`1
MO7"B"04@%.*+X(C3(Y4X5,C=<#GB^0)OO15`68(_?JCGFR5)0*:A@9)8I0LJ
MV4EH`HX^"6-IHZU@(PHX6M!>$J7%14`I&_W$WZ!"_GBHF8@NV@*+?.D0::)0
M%E*II:J:D&D%FP:!7Q?L2!!F'4,=!Z>AXA4W+*`Y].I"'ZTNY-__L7'JZ,*E
MS>(@`H=$9%!`(;VZ=!FT%4CJI7BP4H`M"Y$Y5L$HCHG;`DF>T0FIE:1BJ2(G
M?$A`DH98]"6L6PGZLT:\,ZZYJ@[*BH!FH<\R#`.\+U!KZZ\*$*EN$*-(0$G"
M=TA<:KWC,D'P!.5<3$*;.8!G`9$=N8MNN1/66L*M$1JB<AHK!C:@J'FXV7`"
M(?`V\@2:_0$?(3?;ZQY+BO5RYV;G764@S%/72:^U(ZP&!GJ&*E9,!?@@,-E[
MH&00310+FXQ%J!92O-K09P[FA:.&QN;%U_^&IK8"$$\K<]L@@[V%;`FT:#=A
M\YG[MTSU:+5DT"&A$``!!I3FQGM>;3O'_V1[:]8%SR1L_`(E_*8*<(>5Z_5G
M@M%URL.G'Y]NA[$06B7U"^3=WM5T5^U=0>Y7[;APZ5(@MOOQ0O2-QH,<(^_\
MP2G7T9;OSU<?`I)G'-.X]=Q+@O`9Z78O?@JC$"]$6W2/KSX%%@O%[/KP9]U'
MET*L9GX9NM/R`50T<'W!-E583?HL(#<_^&X)`V3?X$K"!0.:0&[.`EQA))>Z
M_/"`?A(XB&%ND,!EW<LKHBF3[+12P34X"AD8W!,?6D2"&RBK$W";``=GP(4#
ME,(169I!#EL%NA0,(PPS4L%!Y#)#(^S0<0V,`CT>N!D*J"M&"-(#,F@%!@+8
MH(DF*")>,&*!&O^FX(@S<\M8^&4L%EJIBAW@0@=;`$83L<9J2R3!,)(F`BC2
M,0::F57,JF@#+N!M!%H$'$"\B((V<@>-JW.<C%YP$$0.;HTL,"1<@-8)*&#M
M3BE\#"LRN9S8'("3^II7P4390E*NAPL<HT?S1B!)_\3P>FZA7HB(:,HAM%)1
MFG3+)17F1TY2QQ-`A`$`4&8P*G+``+'X9!9KF;4;H#%UEOCB!YO5AFJ:<66:
MFPP<>M@V6D)R!;><QRZ)Z15GOH%R="@!,0T1S!4$0',[^";KQN(!ZFW`?!L8
M(R@YD,E\TE.>_B2+:A+I)8*>KYUSX<!N"'!'"V1`GQTJ#10PB)W#13$]?AB%
MTCIWT(/WP&=77Y!G1D>*`0@2K@E_)*E*6?!.U^4&H2N-Z:I2=U($^$"F.-W%
/`*(3&[%-IBPY#6H$```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
